Business Context and Reporting Period
Company: ENDRA Life Sciences Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 18, 2020
Reporting Period: The filing reports on an event occurring on September 18, 2020, with an effective termination date of September 25, 2020.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding a specific corporate action rather than a periodic financial report.
Material Changes
The Company terminated its "At The Market" (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. Key details include:
- Original Agreement: Entered into on March 27, 2020, allowing the sale of up to $7.2 million of common stock.
- Action Taken: Written notice of termination was delivered on September 18, 2020.
- Effective Date: The termination is effective September 25, 2020.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or specific risk factors beyond the cessation of the ATM offering program. The Company is identified as an emerging growth company.
Investor Verification Checklist
- Verify the status of the Company's cash reserves and capital needs following the termination of the ATM facility.
- Review the original ATM Agreement filed as Exhibit 1.1 to the March 27, 2020, Form 8-K for any remaining obligations or penalties associated with early termination.
- Confirm if the Company has announced alternative financing strategies to replace the terminated $7.2 million offering capacity.